Bausch & Lomb Ophthalmic ZyLET Is “Approvable” At FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
The company expects to launch the anti-inflammatory/antibiotic agent Zylet by year-end. Bausch & Lomb acquired rights to the loteprednol ophthalmic business from Pharmos.